Read by QxMD icon Read


Qun Yan, Melissa J Karau, Robin Patel
We tested the in vitro activity of oritavancin against 185 staphylococci associated with prosthetic joint infection, including 37 methicillin-resistant S. aureus, 67 methicillin-susceptible S. aureus, 59 methicillin-resistant S. epidermidis (MRSE), and 22 methicillin-susceptible S. epidermidis (MSSE) isolates. The oritavancin MIC50 for S. aureus and MSSE was 0.03 μg/mL, and for MRSE, it was 0.06 μg/mL; MIC90 for S. aureus and S. epidermidis was 0.12 μg/mL for both the methicillin-resistant and -susceptible subgroups...
May 18, 2018: Diagnostic Microbiology and Infectious Disease
Nicholas J Mercuro, Susan L Davis, Marcus J Zervos, Erica S Herc
The role of enterococci in infectious diseases has evolved from a gut and urinary commensal to a major pathogen of concern. Few options exist for resistant enterococci, and appropriate use of the available agents is crucial. Areas covered: Herein, the authors discuss antibiotics with clinically useful activity against Enterococcus faecalis and E. faecium. The article specifically discusses: antibiotics active against enterococci and their mechanism of resistance, pharmacokinetic and pharmacodynamic principles, in vitro combinations, and clinical studies which focus on urinary tract, intra-abdominal, central nervous system, and bloodstream infections due to enterococci...
June 7, 2018: Expert Opinion on Pharmacotherapy
Greta Flüh, Harald Seifert, Achim J Kaasch
No abstract text is available yet for this article.
May 25, 2018: Future Microbiology
Wei-Yan Wang, Song-Bai Yang, Yuan-Jie Wu, Xiao-Fang Shen, Shao-Xin Chen
The glycopeptide antibiotic A82846B (chloroeremomycin) produced by Amycolatopsis orientalis is the precursor of the semi-synthetic antibiotic oritavancin. However, during the industrial production of A82846B, two major impurities, A82846A (63.6%) and A82846C (12%) which are structurally similar to A82846B (24.4%), are also produced. In this study, to improve the ratio of A82846B to A and C, the genes encoding halogenase in A82846B and vancomycin synthesis were integrated into A. orientalis SIPI18099 to test their halogenation ability, respectively...
July 2018: Applied Microbiology and Biotechnology
Aleksandr Ianevski, Eva Zusinaite, Suvi Kuivanen, Mårten Strand, Hilde Lysvand, Mona Teppor, Laura Kakkola, Henrik Paavilainen, Mira Laajala, Hannimari Kallio-Kokko, Miia Valkonen, Anu Kantele, Kaidi Telling, Irja Lutsar, Pille Letjuka, Natalja Metelitsa, Valentyn Oksenych, Magnar Bjørås, Svein Arne Nordbø, Uga Dumpis, Astra Vitkauskiene, Christina Öhrmalm, Kåre Bondeson, Anders Bergqvist, Tero Aittokallio, Rebecca J Cox, Magnus Evander, Veijo Hukkanen, Varpu Marjomaki, Ilkka Julkunen, Olli Vapalahti, Tanel Tenson, Andres Merits, Denis Kainov
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus...
June 2018: Antiviral Research
Qun Yan, Melissa J Karau, Robin Patel
We tested the in vitro activity of oritavancin against 60 vancomycin-susceptible enterococci (VSE) and 27 vancomycin-resistant enterococci (VRE). The oritavancin MIC ranged from ≤0.002 to 0.5μg/mL; the minimum biofilm bactericidal concentration ranged from ≤0.002 to 2μg/mL. Oritavancin has promising in vitro activity against VSE and VRE in both planktonic and biofilm states.
March 16, 2018: Diagnostic Microbiology and Infectious Disease
Sierra Bowden, Christine Joseph, Shengzhuang Tang, Jayme Cannon, Emily Francis, Michelle Zhou, James R Baker, Seok Ki Choi
Despite its potent antibacterial activities against drug-resistant Gram-positive pathogens, oritavancin remains partially understood with respect to its primary mode of hydrogen bond interaction with a cell-wall peptide regarding the role of its lipophilic 4'-chlorobiphenyl moiety. Here we report a surface plasmon resonance (SPR) study performed in two cell-wall model surfaces, each prepared by immobilization with a vancomycin-susceptible Lys-d-Ala-d-Ala or vancomycin-resistant Lys-d-Ala-d-Lac peptide. Analysis of binding kinetics performed on the peptide surface showed that oritavancin bound ∼100-1000-fold more tightly than vancomycin on each model surface...
May 8, 2018: Biochemistry
M A Pfaller, H S Sader, R K Flamm, M Castanheira, Rodrigo E Mendes
The in vitro activity of oritavancin was assessed against 44,715 gram-positive pathogens causing infections in European and United States (US) hospitals (2010-2014). There were no substantive differences (>±2-fold dilution) in oritavancin MIC50 or MIC90 values for different species/organism groups over time or by region. Oritavancin (99.9% susceptible) showed modal MIC, MIC50 , and MIC90 results of 0.03, 0.03, and 0.06-0.12 mg/L when tested against Staphylococcus aureus, regardless of methicillin susceptibility, year, or region...
June 2018: Diagnostic Microbiology and Infectious Disease
Ana Alejandra García Robles, Eduardo López Briz, María Dolores Fraga Fuentes, Rocío Asensi Diez, Jesús Francisco Sierra Sánchez
OBJECTIVE: To assess critically oritavancin, a second-generation  lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. METHOD: An evaluation report of oritavancin in Acute Bacterial Skin and Skin  Structure Infections was carried out according to the methodology of the Group  for drug evaluation, standardization and research in drug selection of the  Spanish Society of Hospital Pharmacy (SEFH)1, with the MADRE 4...
March 1, 2018: Farmacia Hospitalaria
Samantha Rosenthal, Arnold G Decano, Aiman Bandali, Denise Lai, Gregory E Malat, Tiffany E Bias
Oritavancin (Orbactiv): a new-generation lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.
March 2018: P & T: a Peer-reviewed Journal for Formulary Management
Giorgia Letizia Marcone, Elisa Binda, Francesca Berini, Flavia Marinelli
Glycopeptide antibiotics are drugs of last resort for treating severe infections caused by multi-drug resistant Gram-positive pathogens. First-generation glycopeptides (vancomycin and teicoplanin) are produced by soil-dwelling actinomycetes. Second-generation glycopeptides (dalbavancin, oritavancin, and telavancin) are semi-synthetic derivatives of the progenitor natural products. Herein, we cover past and present biotechnological approaches for searching for and producing old and new glycopeptide antibiotics...
March 2018: Biotechnology Advances
Rupak Datta, Dayna McManus, Jeffrey Topal, Manisha Juthani-Mehta
Administering and monitoring intravenous antimicrobials may cause discomfort in patients at the end of life and delay transition to hospice. We describe 3 patients with terminal cancer with methicillin-resistant Staphylococcus aureus, Streptococcus gallolyticus , and Granulicatella adiacens bacteremia who were managed with the long-acting lipoglycopeptide oritavancin to facilitate discharge to hospice.
January 2018: Open Forum Infectious Diseases
Qun Yan, Melissa J Karau, Robin Patel
Oritavancin is a recently-approved lipoglycopeptide with activity against Gram-positive bacteria (1).….
January 24, 2018: Journal of Clinical Microbiology
Mark A T Blaskovich, Karl A Hansford, Mark S Butler, ZhiGuang Jia, Alan E Mark, Matthew A Cooper
Glycopeptide antibiotics (GPAs) are a key weapon in the fight against drug resistant bacteria, with vancomycin still a mainstream therapy against serious Gram-positive infections more than 50 years after it was first introduced. New, more potent semisynthetic derivatives that have entered the clinic, such as dalbavancin and oritavancin, have superior pharmacokinetic and target engagement profiles that enable successful treatment of vancomycin-resistant infections. In the face of resistance development, with multidrug resistant (MDR) S...
February 19, 2018: ACS Infectious Diseases
G Ralph Corey, Jeffery Loutit, Greg Moeck, Matthew Wikler, Michael N Dudley, William O'Riordan
Oritavancin is a lipoglycopeptide with bactericidal activity against Gram-positive organisms. Its rapid concentration-dependent bactericidal activity and long elimination half-life allow single-dose treatment of acute bacterial skin and skin structure infections (ABSSSI). SOLO I and SOLO II were randomized, double-blind studies evaluating the efficacy and safety of a single 1,200-mg intravenous (i.v.) dose of oritavancin versus twice-daily i.v. vancomycin for 7 to 10 days in ABSSSI patients. Safety data from both studies were pooled for safety analysis...
April 2018: Antimicrobial Agents and Chemotherapy
C H Chilton, D S Pickering, J Freeman
BACKGROUND: Recurrent Clostridium difficile infection (rCDI) places a huge economic and practical burden on healthcare facilities. Furthermore, rCDI may affect quality of life, leaving patients in an rCDI cycle and dependant on antibiotic therapy. AIMS: To discuss the importance of microbiologic factors in the development of rCDI. SOURCES: Literature was drawn from a search of PubMed from 2000 onwards with the search term 'recurrent Clostridium difficile infection' and further references cited within these articles...
May 2018: Clinical Microbiology and Infection
Lucas T Schulz, Emily Dworkin, Jennifer Dela-Pena, Warren E Rose
OBJECTIVE: Oritavancin is a lipoglycopeptide antibiotic approved for use in acute bacterial skin and skin structure infections as a single 1200-mg parenteral dose. Because of oritavancin's long half-life and broad gram-positive activity, interest in its use for other infections is high. METHODS: This study is a retrospective cohort evaluation of patients receiving oritavancin at a single academic medical center. All patients receiving more than one dose of oritavancin were included...
January 2018: Pharmacotherapy
Adam Belley, Francis F Arhin, Greg Moeck
The clinical development of nonsusceptibility to the lipopeptide antibiotic daptomycin remains a serious concern during therapy for infections caused by vancomycin-resistant Enterococcus faecium (VREfm). The long-acting lipoglycopeptide oritavancin exhibits potent in vitro activity against VREfm, although its safety and efficacy for treating clinical VREfm infections have not been established. In this study, novel dosing regimens of daptomycin and oritavancin were assessed against both VREfm and daptomycin-nonsusceptible VREfm isolates in an in vitro pharmacokinetic/pharmacodynamic model...
January 2018: Antimicrobial Agents and Chemotherapy
Sylvain A Lother, Natasha Press
PURPOSE OF THE REVIEW: Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a common cause of morbidity and mortality. First-line treatment requires frequent daily doses of an anti-staphylococcal beta-lactam. However, some physicians prescribe simpler once-daily regimens to improve compliance and improve healthcare utilization. We reviewed the literature regarding advantages, pitfalls, and efficacy of once-daily treatment options for MSSA bacteremia. RECENT FINDINGS: Several once-daily antibiotics are effective in vitro against MSSA (ceftriaxone, daptomycin, telavancin, dalbavancin, oritavancin, tedizolid, ertapenem, fluoroquinolones, and others), but there is insufficient evidence to support these agents for MSSA bacteremia...
September 23, 2017: Current Infectious Disease Reports
R Agarwal, S M Bartsch, B J Kelly, M Prewitt, Y Liu, Y Chen, C A Umscheid
OBJECTIVES: Skin and soft tissue infections (SSTIs) carry significant economic burden, as well as morbidity and mortality, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA). Several new MRSA-active antibiotics have been developed, including semisynthetic glycopeptides (telavancin, dalbavancin and oritavancin). Of these, dalbavancin and oritavancin offer extended dosing intervals. METHODS: We performed a systematic review, network meta-analysis and cost analysis to compare the newer glycopeptides to standard care and to each other for the treatment of complicated SSTIs (cSSTI)...
April 2018: Clinical Microbiology and Infection
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"